Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-26
2011-11-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S259100, C514S300000, C514S387000, C544S281000, C544S349000, C546S121000, C548S304400
Reexamination Certificate
active
08067415
ABSTRACT:
The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.
REFERENCES:
patent: 4237272 (1980-12-01), Mochida et al.
patent: 4309546 (1982-01-01), Karrer
patent: 5338853 (1994-08-01), MacLeay et al.
patent: 5356904 (1994-10-01), Freidinger et al.
patent: 5397821 (1995-03-01), MacLeay et al.
patent: 5688960 (1997-11-01), Shankar
patent: 5696267 (1997-12-01), Reichard et al.
patent: 6143750 (2000-11-01), Patane et al.
patent: 6225324 (2001-05-01), Poss et al.
patent: 6313117 (2001-11-01), Bekkali et al.
patent: 6369077 (2002-04-01), Marquis et al.
patent: 6627629 (2003-09-01), Ko et al.
patent: 6649642 (2003-11-01), Bekkali et al.
patent: 6720319 (2004-04-01), Liu et al.
patent: 6740649 (2004-05-01), Ott et al.
patent: 6743807 (2004-06-01), Duan et al.
patent: 6858623 (2005-02-01), Bekkali et al.
patent: 6949546 (2005-09-01), Ko et al.
patent: 6979690 (2005-12-01), Gymer et al.
patent: 6979741 (2005-12-01), Perry et al.
patent: 6984648 (2006-01-01), Lu et al.
patent: 7163937 (2007-01-01), Carter et al.
patent: 7169795 (2007-01-01), Han et al.
patent: 7183270 (2007-02-01), Cherney et al.
patent: 7307086 (2007-12-01), Xue et al.
patent: 7312218 (2007-12-01), Han et al.
patent: 7338947 (2008-03-01), Cherney et al.
patent: 7378409 (2008-05-01), Carter et al.
patent: 2005/0176738 (2005-08-01), Goodfellow et al.
patent: 2006/0135575 (2006-06-01), Carayon et al.
patent: 2007/0179126 (2007-08-01), Casellas et al.
patent: 2009/0197884 (2009-08-01), Ghosh et al.
patent: 2010/0016289 (2010-01-01), Sprott et al.
patent: 382185 (1990-08-01), None
patent: 516192 (1992-12-01), None
patent: 1325921 (2003-07-01), None
patent: 63083082 (1988-04-01), None
patent: 10298180 (1998-11-01), None
patent: WO 95/08533 (1995-03-01), None
patent: WO 95/19773 (1995-07-01), None
patent: WO 96/34856 (1996-11-01), None
patent: WO 97/48397 (1997-12-01), None
patent: WO 97/48695 (1997-12-01), None
patent: WO 97/48696 (1997-12-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 98/57640 (1998-12-01), None
patent: WO 99/53920 (1999-10-01), None
patent: WO 00/44376 (2000-08-01), None
patent: WO 00/69816 (2000-11-01), None
patent: WO 01/09110 (2001-02-01), None
patent: WO 01/19816 (2001-03-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 02/02525 (2002-01-01), None
patent: WO 02/13824 (2002-02-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/062784 (2002-08-01), None
patent: WO 03/024899 (2003-03-01), None
patent: WO 03/057688 (2003-07-01), None
patent: WO 03/072197 (2003-09-01), None
patent: WO 03/075853 (2003-09-01), None
patent: WO 03/076403 (2003-09-01), None
patent: WO 03/092586 (2003-11-01), None
patent: WO 03/093231 (2003-11-01), None
patent: WO 03/093266 (2003-11-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/041161 (2004-05-01), None
patent: WO 2004/041163 (2004-05-01), None
patent: WO 2004/041777 (2004-05-01), None
patent: WO 2004/050024 (2004-06-01), None
patent: WO 2004/071449 (2004-08-01), None
patent: WO 2004/071460 (2004-08-01), None
patent: WO 2004/076411 (2004-09-01), None
patent: WO 2004/081005 (2004-09-01), None
patent: WO 2004/082616 (2004-09-01), None
patent: WO 2004/082682 (2004-09-01), None
patent: WO 2004/092124 (2004-10-01), None
patent: WO 2004/094371 (2004-11-01), None
patent: WO 2004/096798 (2004-11-01), None
patent: WO 2004/098512 (2004-11-01), None
patent: WO 2004/098516 (2004-11-01), None
patent: WO 2005/010154 (2005-02-01), None
patent: WO 2005/014537 (2005-02-01), None
patent: WO 2005/020899 (2005-03-01), None
patent: WO 2005/021498 (2005-03-01), None
patent: WO 2005/021500 (2005-03-01), None
patent: WO 2005/037216 (2005-04-01), None
patent: WO 2005/047293 (2005-05-01), None
patent: WO 2005/048922 (2005-06-01), None
patent: WO 2005/060665 (2005-07-01), None
patent: WO 2005/070133 (2005-08-01), None
patent: WO 2005/072361 (2005-08-01), None
patent: WO 2005/077369 (2005-08-01), None
patent: WO 2005/079519 (2005-09-01), None
patent: WO 2005/080371 (2005-09-01), None
patent: WO 2005/105092 (2005-11-01), None
patent: WO 2005/115392 (2005-12-01), None
patent: WO 2005/117890 (2005-12-01), None
patent: WO 2005/120505 (2005-12-01), None
patent: WO 2006/001958 (2006-01-01), None
patent: WO 2006/004684 (2006-01-01), None
patent: WO 2006/004741 (2006-01-01), None
patent: WO 2007/053495 (2007-05-01), None
patent: WO 2007/053498 (2007-05-01), None
patent: WO 2007/072201 (2007-06-01), None
Office Action dated Jun. 30, 2010 (Part of Paper No. 20100519) in U.S. Appl. No. 12/084,356, filed Apr. 15, 2009.
Butler, Todd W., et al., “(3R,4S)-3-[4-(4-Fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: A Conformationally Restricted Analogue of the NR2B Subtype-Selective NMDA Antagonist (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol,”Journal of Medicinal Chemistry, vol. 41, No. 7 (1998) pp. 1172-1184.
Feria, Manuel, et al., “The CCR2 receptor as a therapeutic target,”Expert Opinion on Therapeutic Patents, vol. 16, No. 1 (2006) pp. 49-57.
Grey, Jonathan, et al., “Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1receptor antagonists,”Bioorganic&Medicinal Chemistry Letters, vol. 15, No. 4 (2005) pp. 999-1004.
Stephen, John F., et al., “Preparation of bicyclic enamines and their reaction with sulfene,”Journal of Organic Chemistry, vol. 34, No. 9 (Sep. 1969) pp. 2535-2542.
Ting, Pauline C., et al., “The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists,”Bioorganic&Medicinal Chemistry Letters, vol. 15, No. 5 (2005) pp. 1375-1378.
Torii, Sigeru, et al., “Penicillin-cephalosporin conversion. X. New synthesis of dithioazetidinones from thiazoline-azetidinones,”Tetrahedron Letters, vol. 25, No. 19 (1984) pp. 2017-2020.
Woods, J.H., et al., “Evaluation of new compounds for opioid activity,”NIDA Research Monograph, vol. 179 (Problems of drug dependence, 1998) pp. 365-380.
Yang, Yulong, et al., “Synthesis and anesthetic activity of 3-methyl fentanyl derivatives,”Zhongguo Yaoke Daxue Xuebao, vol. 24, No. 5 (1993) pp. 257-263.
International Search Report and Written Opinion dated Apr. 20, 2007 cited in corresponding PCT application PCT/US06/042181 (WO07/053499).
International Search Report and Written Opinion dated Mar. 30, 2007 cited in PCT application PCT/US06/042180 (WO07/053498).
International Search Report and Written Opinion dated May 10, 2007 cited in PCT application PCT/US06/042170 (WO07/053495).
Office Action dated Feb. 24, 2011 (Part of Paper No. 20110104-A) in U.S. Appl. No. 12/084,356 (filed Apr. 15, 2009).
Elder Amy M.
Ghosh Shomir
Griffiths Sian
Raman Prakash
Soucy Francois
Anderson Rebecca
Millennium Pharmaceuticals Inc.
Shterengarts Samantha
LandOfFree
Compounds useful as antagonists of CCR2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds useful as antagonists of CCR2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful as antagonists of CCR2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285452